- Anti-microbial technology company Byotrol said it expected regulatory delays in the US to exacerbate losses, though revenue was expected in line amid a boost from the contribution with Medimark Scientific.

The company expected to generate consolidated full year revenues of around £4.2m, in line with market expectations and an earnings (EBITDA) loss in the region of £0.450m, increased by the delayed regulatory approval in the US and by higher marketing and research costs in the US.

Looking ahead, the company touted further synergies to be released from the combination with Medimark Scientific.

'The MSL and Byotrol teams are working together well and are uncovering many potential synergies across the Group. We will seek to release these benefits in the new financial year, as the earn-out proceeds towards its conclusion in March 2020,' the company said.

At 9:11am: [LON:BYOT] Byotrol PLC share price was 0p at 2.18p

Story provided by